Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol
Executive Summary
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
You may also be interested in...
Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
A BCMA Setback For Bristol And Bluebird With FDA Refuse-To-File Letter
The US FDA took issue with the CMC portion of the BLA for the BCMA-targeted therapy idecabtagene vicleucel for multiple myeloma. An approval is tied to a $9 CVR for Celgene shareholders.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports